Lamivudine
Lamivudine is an antiviral compound clinically used as a treatment for hepatitis B infection; it acts as a thymidine analog, inhibiting the reverse transcriptase enzyme. In two separate in vitro models, lamivudine decreased HIV production in recently infected resting cells and inhibited growth of HIV-infected cells at low concentrations. Additionally, lamivudine increases insulin resistance when given with zidovudine in clinical settings.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18937486
| Cas No. |
134678-17-4 |
|---|---|
| Purity |
≥98% |
| Formula |
C8H11N3O3S |
| Formula Wt. |
229.26 |
| IUPAC Name |
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one |
| Synonym |
Epivir |
| Appearance |
White to off white powder |
Blümer RM, van Vonderen MG, Sutinen J, et al. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS. 2008 Jan 11;22(2):227-36. PMID: 18097225.
Saavedra-Lozano J, McCoig CC, Cao Y, et al. Zidovudine, lamivudine, and abacavir have different effects on resting cells infected with human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 2004 Aug;48(8):2825-30. PMID: 15273087
Balestrieri E, Forte G, Matteucci C, et al. Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro. Antimicrob Agents Chemother. 2002 Sep;46(9):3080-3. PMID: 12183277.
